Clinical and molecular spectrum of VEXAS with multiple UBA1 variants: case study and literature review
American Journal of Clinical Pathology · 2026
DOI: 10.1093/ajcp/aqag097 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Clinical Pathology, 2026. Verfasst von Riku Das und 7 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pathology and Cytogenomics, Robert J. Tomsich Division of Pathology & Laboratory Medicine, Diagnostics Institute, Cleveland Clinic, Clevela…. Hauptthemen laut MEDLINE: Ubiquitin-Activating Enzymes, Inflammation, Genetic Diseases, X-Linked. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Objectives
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a rare adult-onset autoinflammatory disorder, caused by a single somatic UBA1 mutation. We report a novel case with 3 independent UBA1-mutated clones and compare its clinical, hematologic, and laboratory features with those of the only 3 previously reported cases harboring multiple UBA1 mutations.
Methods
Droplet digital polymerase chain reaction (PCR) and targeted next-generation sequencing of peripheral blood DNA were performed to assess UBA1 variants. Bone marrow specimens were evaluated for morphologic, immunophenotypic, and cytogenetic abnormalities.
Results
Clinical and hematologic features included neck swelling, headache, elevated inflammatory markers, leukopenia, macrocytic anemia, and thrombocytopenia. Bone marrow biopsy specimens showed no dysplasia, increased blasts, or cytoplasmic vacuolization. Droplet digital PCR detected atypical positive signals across multiple targets, and next-generation sequencing identified 3 presumed independent UBA1 variants: p.M41V, p.M41L, and c.118-2A > T. Comparison with 3 previously reported VEXAS cases carrying multiple UBA1 variants revealed diverse clinical manifestations, including systemic inflammation, polychondritis, venous thromboembolism, arthritis, and arthralgia, with variable hematologic findings ranging from no neoplasm to myelodysplastic syndrome or multiple myeloma, as well as co-occurring clonal hematopoietic variants.
Conclusions
This report describes a novel VEXAS case with multiple UBA1 variants and highlights the clinical and hematologic heterogeneity among patients harboring multiple UBA1 mutations. It also emphasizes the technical challenges in detecting these variants and the importance of sequencing studies for definitive diagnosis in complex or equivocal cases, supporting early identification of UBA1 mutations and closer hematologic surveillance in patients with inflammatory symptoms and cytopenias.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Pathology and Cytogenomics, Robert J. Tomsich Division of Pathology & Laboratory Medicine, Diagnostics Institute, Cleveland Clinic, Cleveland, OH, United States.
- Department of Pathology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.
Zitieren
APA
Das, R., Prisneac, I., Calvaresi, E., Mularo, F., Pohl, J., Wensel, C., Press, R. D., & Bosler, D. S. (2026). Clinical and molecular spectrum of VEXAS with multiple UBA1 variants: case study and literature review. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqag097
Vancouver
Das R, Prisneac I, Calvaresi E, Mularo F, Pohl J, Wensel C, et al. Clinical and molecular spectrum of VEXAS with multiple UBA1 variants: case study and literature review. American Journal of Clinical Pathology. 2026. doi:10.1093/ajcp/aqag097
BibTeX
@article{Das2026,
author = {Das, Riku and Prisneac, Ion and Calvaresi, Emilia and Mularo, Frank and Pohl, Jonathan and Wensel, Christine and Press, Richard D and Bosler, David S},
title = {Clinical and molecular spectrum of VEXAS with multiple UBA1 variants: case study and literature review},
journal = {American Journal of Clinical Pathology},
year = {2026},
doi = {10.1093/ajcp/aqag097}
}
EUVIMED